MedTrace Logo

A Pharmacokinetics Study of MultiHance in Pediatric Patients

NCT00411931 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2008-01-11

No results posted yet for this study

Summary

Compare relative exposure in the younger age group in order to supplement the PK profile already determined in older children and adults

Conditions

  • Central Nervous System Pathology

Interventions

DRUG

Multihance

0.5M administered as a single injection

Sponsors & Collaborators

  • Bracco Diagnostics, Inc

    lead INDUSTRY

Principal Investigators

  • Gianpaolo Pirovano, M. D. · Bracco Diagnostics, Inc

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Max Age
5 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2007-12-31
Completion
2007-12-31

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00411931 on ClinicalTrials.gov